Increased expression of EZH2, a polycomb group protein, in bladder carcinoma

Urologia Internationalis

Volumn 75, Issue 3, 2005, Pages 252-257

  Arisan, Serdar ^a,c   Buyuktuncer, Elif Damla ^b   Palavan Unsal, Narcin ^b   Çaşkurlu, Turhan ^a   Çakir, Omer Onur ^a   Ergenekon, Erbil ^a  

^a SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b HALIC UNIVERSITY   (Turkey)

^c Uroloji Klinigi Sisli ^*  (Turkey)

Author keywords

Bladder; Enhancer zeste homolog 2; EZH2 gene expression; EZH2, polycomb group protein; RT PCR

Indexed keywords

ENHANCER ZESTE HOMOLOG 2 PROTEIN; GENE PRODUCT; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; TRANSITIONAL CELL CARCINOMA; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CARCINOMA, TRANSITIONAL CELL; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 26444477288     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000087804     Document Type: Article

References (18)

1. Varambally S, Dhanasekeran SM, Zhou M, Barette TR, Kumar Sinha G, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM: The PcG group of protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629.
2. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-5235.
3. Cardoso C, Mginon C, Hetet G, Grandchamps B, Fontes M, Colleaux J: The human EZH2 gene: genomic organization and revised mapping in 7q35 within a critical region of malignant disorders. Eur J Hum Genet 2000;8:174-180.
4. Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA: Multiplex biomarker approach for determining risk of prostate-specific antigen defined recurrence of prostate cancer. J Natl Cancer Inst 2003;95:661-667.
5. Raaphorst FM, Meijer CJLM, Fieret E, Blokzijl T, Mommers E, Buerger H, Packeinsen J, Sewalt RGAB, Otte AP, van Diest PJ: Poorly differentiated breast carcinoma is associated with increased expression of human polycomb group EZH2 gene. Neoplasia 2003;5:481-488.
6. Kirmizis A, Bartley SM, Farnham PJ, Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM: Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Can Ther 2003;2:113-121.
7. Raaphorst FM, Meijer CJ, Willemze R, Otte CJ: The polycomb group protein EZH2 upregulated in proliferating, cultured human mantle cell lymphoma. Br J Heamatol 2001;112:950-958.
8. Raghavan D, Skinner E: Genitourinary cancer in the elderly. Semin Oncol 2004;31:249-263.
9. Bradford M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
10. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RGAB, Otte AP, Hayes DF, Sabel MS, Livant D, Weiss SJ, Rubin MA, Chinnaiyan AM: EZH2 is a marker of aggressive breast cancer and promoter neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 2003;100:11606-11111.
11. Sellers WR, Loda M: The EZH2 polycomb transcriptional repressor - a marker or mover of metastatic prostate cancer? Cancer Cell 2002;2:349-350.
12. Tang X, Milyavsky M, Shats I, Erez N, Goldfinger N, Rotter V: Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 2004;23:5759-5769.
13. Fukuyama T, Otsuka T, Shigematsu H, Uchida N, Arima F, Ohno Y, Iwasaki H, Fukuda T, Niho Y: Proliferative involvement of ENX-1, a putative human PcG group gene, in haematopoietic cells. Br J Haematol 2000;108:842-847.
14. Sewalt RGAB, van der Vlag J, Gunster MJ, Hamer KM, den Blaauwen JL, Satjin DPE, Hendrix T, van Driel R, Otte AP: Characterization of interactions between the mammalian polycomb group proteins Enx1/EZH2 and EED suggest the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol 1998;18:3586-3595.
15. Raaphorst FM, Otte AP, Meijer JLM: PcG group genes as regulators of mammalian lymphopoiesis. Trends Immunol 2001;22:682-689.
16. Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satjin DP, Otte AP, Meijer CJ: Coexpression of BMI1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000;157:709-715.
17. Van Veer LJ, Dai H, van de Vijver HJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witheeven AT: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-536.
18. Jacobs JJ, van Lohuizen M: PcG repression: From cellular memory to cellular proliferation and cancer. Biochim Biophys Acta 2002;1602:151-161.